Back to results
US 2016/0355815 A1Published application
miR-29 Mimics and Uses Thereof
AssigneeMiragen Therapeutics, Inc.
InventorsRusty L. MONTGOMERY, Christina M. DALBY, Eva VAN ROOIJ, Corrie GALLANT-BEHM
Life of this patent
Estimating the term…
Abstract
The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.
Claims29
A miR-29 mimetic compound comprising:
- a first strand of about 23 to about 26 ribonucleotides comprising a mature miR-29a, miR-29b, or miR-29c sequence;
- and
- a second strand of about 22 to about 23 ribonucleotides comprising a sequence that is substantially complementary to the first strand and having at least one modified nucleotide, wherein the first strand has a 3′ nucleotide overhang relative to the second strand.
Dependencies are inferred from the claim text.